May 17, 2023 - May 19, 2023

Remus Pharmaceuticals IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Remus Pharmaceuticals IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	0	0	1	0
%	0.00	0.00	0.00	100.00	0.00

Remus Pharmaceuticals IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	Avoid

Remus Pharmaceuticals IPO Review by Dilip Davda (Avoid)

[Dilip Davda] The company is in a highly competitive and fragmented segment of pharma product distribution with third-party contracts under the B2B model. Its profit margins are non-convincing. Based on super profits the issue appears fully priced. The sustainability of margins is a major concern. There is no harm in skipping this tricky issue that will have a longer gestation period for migration to the main board as post IPO its paid-up equity capital is just under Rs. 1.5 cr. Read detail review...

Remus Pharmaceuticals IPO Peer Comparison

Remus Pharmaceuticals Limited peer comparison with similar listed entities. (Standalone) (As on March 31, 2022)

Company Name	EPS (Rs)	NAV (per share) (Rs)	P/E (x)	RoNW (%)
Company Name	EPS Basic	NAV (per share) (Rs)	P/E (x)	RoNW (%)
Remus Pharmaceuticals Limited	33.86	64.30		52.64
Trident Lifeline Limited	6.92	5.97	21.46	82.66
Vaishali Pharma Limited	3.82	24.99	42.68	15.27
Chandra Bhagat Pharma Limited	1.06	35.35	99.06	2.99

Remus Pharmaceuticals IPO Review by Members

Remus Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Remus Pharmaceuticals Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Remus Pharmaceuticals IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	2	0	1	2
%	40.00	0.00	20.00	40.00

Member	Review
SuppuR	Apply for Long Term at Upper Price Band Good Valuation, For Long term one of the multi-bagger... 1 May 10, 2023 5:01:50 PM
Baron	Apply for Listing Gain at Upper Price Band Will gain a lot 1 May 12, 2023 8:12:59 PM
B.M.SURANA IPO Guru (2700+ Posts, 5300+ Likes)	Neutral Costly lagta hai. Jo risk leten hai Wo hi apply karenge! 3 May 15, 2023 5:00:16 PM
Akki	Avoid Price band is very high 1 May 16, 2023 12:34:31 PM
Advik rastogi	Avoid Income tax demand on group company RATNATRIS PHARMACEUTICALS PRIVATE LIMITED of rs 21.50 cr litigation while the remus pharma Company networth is only 17 cr there are high chances of spillover of group company ratnatris liability to renus so this issue should be given a skip May 10, 2023 10:39:21 PM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

1 Comments

1. N Link|May 16, 2023 7:20:26 PM

Phone NUmber not working